Please select the option that best describes you:
How do you reconcile data from PATINA trial and DESTINY-Breast09 with respect to CDK4/6 inhibitor maintenance in metastatic HER 2+ breast cancer?
Can CDK4/6 inhibitors be added to TDxd
Can CDK4/6 inhibitors be added to TDxd